Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Hereditary Actionable Disorders Screen (HADS) Inherited Predisposition Screening (IPS) Variant Panel Market Forecast: What Value Will The Market Reach By 2030?
The hereditary actionable disorders screen (HADS) inherited predisposition screening (IPS) variant panel market size has witnessed substantial growth in recent years. It will grow from $1.29 billion in 2025 to $1.45 billion in 2026 at a compound annual growth rate (CAGR) of 12.3%. The expansion observed in the past can be attributed to increased awareness of hereditary cancer syndromes, the proliferation of clinical genetic testing services, the decreasing cost of sequencing technologies, a rise in the prevalence of inherited cardiovascular disorders, and the increasing adoption of evidence-based screening guidelines.
The market for the hereditary actionable disorders screen (HADS) inherited predisposition screening (IPS) variant panel is anticipated to undergo rapid expansion in the coming years. It is projected to reach $2.32 billion in 2030, showing a compound annual growth rate (CAGR) of 12.6%. This increase during the forecast period is attributable to the expanding integration of genomic data into routine clinical practices, a rising need for population-level genetic screening, increased investments in precision medicine initiatives, the broadening of reimbursement policies for genetic testing, and the continuous development of multi-gene actionable panels. Significant trends over the forecast period involve the growing adoption of targeted germline variant panels, an escalating demand for preventive genetic screening programs, the enhanced integration of hereditary cancer risk assessments, the proliferation of evidence-based clinical intervention protocols, and a heightened emphasis on the early detection of inherited cardiovascular disorders.
Get A Free Sample Report With In-Depth Market Insights:
Hereditary Actionable Disorders Screen (HADS) Inherited Predisposition Screening (IPS) Variant Panel Market Growth Backed By Core Demand Fundamentals
The increasing occurrence of genetic disorders is projected to fuel the expansion of the HADS inherited predisposition screening (IPS) variant panel market. Genetic disorders are conditions stemming from alterations or mutations in an individual’s DNA, which can be passed down from parents or emerge spontaneously. The rise in genetic disorder prevalence is attributed to advancements in genetic testing and screening, leading to the identification of more previously undiagnosed cases, alongside heightened awareness among medical professionals and the public. The HADS IPS variant panel assists in detecting inherited genetic mutations and predispositions in individuals, thereby facilitating early diagnosis, personalized risk evaluation, and informed healthcare decisions to manage or prevent the onset of genetic disorders. For instance, in October 2024, according to the National Health Service (NHS) England, a UK-based government department, as part of a groundbreaking study in NHS hospitals, several hundred newborns have already undergone testing for more than 200 rare genetic conditions, with the initiative aiming to screen up to 100,000 babies across England. Consequently, the growing prevalence of genetic disorders is stimulating the growth of the HADS inherited predisposition screening (IPS) variant panel market. The expanding adoption of personalized medicine is anticipated to drive forward the HADS inherited predisposition screening (IPS) variant panel market. Personalized medicine involves medical treatments specifically designed for individual patients, based on their unique genetic profiles, biomarkers, and molecular characteristics. The increased embrace of personalized medicine is due to innovations in genomic sequencing technologies, which have significantly lowered costs and improved accessibility, enabling widespread genetic profiling in clinical environments. The HADS inherited predisposition screening (IPS) variant panel supports personalized medicine by identifying an individual’s specific genetic risk variants, empowering clinicians to customize prevention tactics, early interventions, and treatment plans uniquely tailored to each patient’s inherited predisposition. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for patients with rare diseases, marking a substantial increase from the six approvals in 2022. Therefore, the increasing adoption of personalized medicine is a key driver for the growth of the HADS inherited predisposition screening (IPS) variant panel market.
Hereditary Actionable Disorders Screen (HADS) Inherited Predisposition Screening (IPS) Variant Panel Market Segment Breakdown: Which Categories Lead On Revenue?
The hereditary actionable disorders screen (HADS) inherited predisposition screening (IPS) variant panel market covered in this report is segmented –
1) By Technology: Polymerase Chain Reaction, Next Generation Sequencing, Microarray, Other Technologies
2) By Product Type: Assay Kits, Reagents, Instruments, Software
3) By Application: Clinical Diagnostics, Research, Personalized Medicine, Oncology, Other Applications
4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Research Institutes, Other End Users
Subsegments:
1) By Polymerase Chain Reaction: Real Time Polymerase Chain Reaction, Digital Polymerase Chain Reaction, Multiplex Polymerase Chain Reaction, Allele Specific Polymerase Chain Reaction, Other Polymerase Chain Reaction Methods
2) By Next Generation Sequencing: Targeted Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Single Cell Sequencing, Other Sequencing Approaches
3) By Microarray: Single Nucleotide Polymorphism Array, Comparative Genomic Hybridization Array, Gene Expression Array, Methylation Array, Other Microarray Technologies
4) By Other Technologies: Hybrid Capture Based, Bead Based Assays, Electrochemical Detection, Optical Detection, Other Emerging Technologies
Hereditary Actionable Disorders Screen (HADS) Inherited Predisposition Screening (IPS) Variant Panel Market Leading Players And Competitive Positioning
Major companies operating in the hereditary actionable disorders screen (HADS) inherited predisposition screening (IPS) variant panel market are Helix Inc.
View The Full Hereditary Actionable Disorders Screen (HADS) Inherited Predisposition Screening (IPS) Variant Panel Market Report:
Hereditary Actionable Disorders Screen (HADS) Inherited Predisposition Screening (IPS) Variant Panel Market Regional Distribution: Which Areas Power Market Growth?
North America was the largest region in the hereditary actionable disorders screen (HADS) inherited predisposition screening (IPS) variant panel market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary actionable disorders screen (HADS) inherited predisposition screening (IPS) variant panel market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

